Wang Yingliang, Song Songlin, Zhou Chen, Zhu Wenying, Liu Jiacheng, Shi Qin, Huang Songjiang, Yang Chongtu, Li Tongqiang, Chen Yang, Xiong Bin
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hubei Key Laboratory of Molecular Imaging, Wuhan, China.
J Endovasc Ther. 2022 Oct;29(5):724-730. doi: 10.1177/15266028211061268. Epub 2021 Dec 1.
To evaluate the safety and efficacy of thoracic endovascular aortic repair (TEVAR) for retrograde type A intramural hematoma (IMH) with intimal disruption in the descending aorta and report our endovascular therapeutic experience.
From January 2014 to October 2020, a total of 24 consecutive patients with retrograde type A IMH with intimal disruption (intimal tear or ulcer-like projection) in the descending aorta underwent TEVAR. The demographics, clinical characteristics, treatment details, imaging information, and follow-up results were reviewed.
Among all patients with retrograde type A IMH, 13 (54.2%) patients presented with ulcer-like projection and 11 (45.8%) with intimal tear (aortic dissection) in the descending aorta. Successful TEVAR was achieved in all patients. There was no 30-day mortality. During a mean follow-up of 37.5 months, 1 patient (4.2%) developed permanent paralysis, 1 patient (4.2%) underwent reintervention due to the expansion of the aorta distal to the stent resulting from the enlargement of distal intimal tear at the 2 month follow up, and no other adverse events were observed. The latest computed tomographic angiography images showed that the maximum diameter of the ascending aorta and descending aorta significantly decreased after TEVAR (both p<0.001), and the IMH/false lumen in the ascending aorta and the descending thoracic aorta were completely absorbed.
Thoracic endovascular aortic repair for selected patients with retrograde type A intramural hematoma that presented with intimal disruption in the descending aorta is feasible and efficient, but close surveillance is needed to manage aortic-related adverse events.
评估胸主动脉腔内修复术(TEVAR)治疗降主动脉逆行性A型主动脉壁内血肿(IMH)合并内膜破裂的安全性和有效性,并报告我们的血管内治疗经验。
2014年1月至2020年10月,共有24例降主动脉逆行性A型IMH合并内膜破裂(内膜撕裂或溃疡样突出)的连续患者接受了TEVAR治疗。回顾了患者的人口统计学资料、临床特征、治疗细节、影像学信息和随访结果。
在所有逆行性A型IMH患者中,13例(54.2%)降主动脉出现溃疡样突出,11例(45.8%)出现内膜撕裂(主动脉夹层)。所有患者TEVAR均成功。无30天死亡率。在平均37.5个月的随访期间,1例患者(4.2%)发生永久性瘫痪,1例患者(4.2%)在随访2个月时因支架远端内膜撕裂扩大导致主动脉远端扩张而接受再次干预,未观察到其他不良事件。最新的计算机断层血管造影图像显示,TEVAR术后升主动脉和降主动脉的最大直径显著减小(均p<0.001),升主动脉和胸降主动脉的IMH/假腔完全吸收。
对于降主动脉出现内膜破裂的选择性逆行性A型主动脉壁内血肿患者,胸主动脉腔内修复术是可行且有效的,但需要密切监测以处理与主动脉相关的不良事件。